BCG vaccine
- Generic Name
- BCG vaccine
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 8VJE55B0VG
- Background
BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.
- Associated Conditions
- Non-Invasive Bladder Urothelial Carcinoma, Recurrent Superficial Bladder Cancer, Tuberculosis (TB), Urothelial Carcinoma Recurrent, Carcinoma in situ of urinary bladder
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 190
- Registration Number
- NCT03022825
- Locations
- 🇺🇸
Integrated Medical Professionals, New York, New York, United States
🇺🇸Alaska Clinical Research Center, Anchorage, Alaska, United States
🇺🇸Arkansas Urology, Little Rock, Arkansas, United States
A Trial Investigating the Influence of BCG and Hepatitis B Immunisation at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study
- Conditions
- Innate Immune Response
- Interventions
- First Posted Date
- 2015-05-14
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- Murdoch Childrens Research Institute
- Target Recruit Count
- 185
- Registration Number
- NCT02444611
- Locations
- 🇦🇺
Mercy Hospital for Women, Heidelberg, Victoria, Australia
Heterologous Effects of BCG in Healthy UK Adults
- Conditions
- Tuberculosis
- Interventions
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 36
- Registration Number
- NCT02380508
- Locations
- 🇬🇧
Centre for Clinical Vaccinology and Tropical Medicine , University of Oxford, Oxford, Oxfordshire, United Kingdom
🇬🇧Oxford University Hospitals- John Warin Ward, University of Oxford, Oxford, Oxfordshire, United Kingdom
🇬🇧NIHR Wellcome Trust Clinical Research Facility, University of Birmingham, Birmingham, West Midlands, United Kingdom
Intravesical BCG Administration to Patients With Invasive Bladder Cancer
- Conditions
- Bladder Cancer
- Interventions
- First Posted Date
- 2015-02-18
- Last Posted Date
- 2019-11-05
- Target Recruit Count
- 6
- Registration Number
- NCT02365207
- Locations
- 🇺🇸
MARC - The University of Texas Health Science Center, San Antonio, Texas, United States
Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects
- Conditions
- Poisoning by BCG Vaccine
- Interventions
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2015-05-28
- Lead Sponsor
- University of Rome Tor Vergata
- Target Recruit Count
- 30
- Registration Number
- NCT02207608
A Clinical Challenge Study of BCG in Healthy Volunteers
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2015-01-22
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 52
- Registration Number
- NCT02088892
- Locations
- 🇬🇧
The Wellcome Trust Clinical Research Facility, University of Birmingham, Birmingham, West Midlands, United Kingdom
🇬🇧Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, Oxfordshire, United Kingdom
Melbourne Infant Study - Bacille Calmette Guérin (BCG) for Allergy & Infection Reduction
- First Posted Date
- 2013-07-24
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Murdoch Childrens Research Institute
- Target Recruit Count
- 1272
- Registration Number
- NCT01906853
- Locations
- 🇦🇺
Mercy Hospital for Women, Heidelberg, Victoria, Australia
🇦🇺Royal Children's Hospital, Melbourne, Victoria, Australia
Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma
- Conditions
- Transitional Cell Carcinoma of Bladder
- Interventions
- First Posted Date
- 2013-06-14
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Anchiano Therapeutics Israel Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT01878188
- Locations
- 🇮🇱
Tel Aviv Medical Center, Tel Aviv, Israel
🇮🇱Carmel Medical Center, Haifa, Israel
🇮🇱Bnai Zion MC, Haifa, Israel
The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- A.O.U. Città della Salute e della Scienza
- Target Recruit Count
- 120
- Registration Number
- NCT01697306
- Locations
- 🇮🇹
A.O.U. San Giovanni Battista Molinette, Torino, TO, Italy
Study of AERAS 422 in Healthy Adults
- First Posted Date
- 2011-04-25
- Last Posted Date
- 2012-08-16
- Lead Sponsor
- Aeras
- Target Recruit Count
- 24
- Registration Number
- NCT01340820
- Locations
- 🇺🇸
St. Louis University Hospital, St. Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.